{
  "run_id": "RUN_20260204_132700_1fed028ce5fb",
  "timestamp": "2026-02-04T14:36:04.886547",
  "document": "01_Article_Iptacopan C3G Trial.pdf",
  "document_path": "/Users/frederictetard/Projects/ese/gold_data/PAPERS/01_Article_Iptacopan C3G Trial.pdf",
  "pipeline_version": "0.8",
  "total_candidates": 32,
  "total_validated": 32,
  "total_rejected": 0,
  "total_ambiguous": 0,
  "diseases": [
    {
      "matched_text": "immune complex membranoproliferative glomerulonephritis",
      "preferred_label": "Immune complex membranoproliferative glomerulonephritis",
      "abbreviation": "IC-MPGN",
      "confidence": 0.9500000000000001,
      "is_rare_disease": false,
      "category": "nephrology",
      "codes": {
        "icd10": "N03.5",
        "icd11": null,
        "snomed": "236403008",
        "mondo": null,
        "orpha": null,
        "umls": null,
        "mesh": null
      },
      "all_identifiers": [
        {
          "system": "ICD-10",
          "code": "N03.5",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "N03.5",
          "display": null
        },
        {
          "system": "SNOMED-CT",
          "code": "236403008",
          "display": null
        }
      ],
      "context": "26 Downward L, Wong K, Proudfoot C, Webb NJA, Wong E, Gale D. Patient characteristics and renal outcomes of C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in the UK: a retrospective analysis of 287 patients in the UK National Registry of Rare Kidney Diseases (RaDaR). J Am Soc Nephrol 2023; 34 (11S): S271-72.",
      "page": 11,
      "mention_count": 3,
      "pages_mentioned": [
        11
      ],
      "lexicon_source": "disease_lexicon_c3g.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "monoclonal gammopathy of undetermined significance",
      "preferred_label": "monoclonal gammopathy of undetermined significance",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0004225",
        "orpha": null,
        "umls": "UMLS:C0026470",
        "mesh": "MESH:D008998"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0004225",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:7442",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:238.6",
          "display": null
        },
        {
          "system": "ICDO",
          "code": "ICDO:9765/1",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:44485",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D008998",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C3996",
          "display": null
        },
        {
          "system": "ONCOTREE",
          "code": "ONCOTREE:MGUS",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:58648008",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0026470",
          "display": null
        }
      ],
      "context": "itidis and Streptococcus pneumoniae before study entry or during the screening period was mandatory. Exclusion criteria included receipt of any cell or solid organ transplantation, rapidly progressive crescentic glomerulonephritis, kidney biopsy showing interstitial fibrosis or tubular atrophy, and monoclonal gammopathy of undetermined significance. The full list of eligibility criteria is available in the appendix (p 6) and further details on the study population are available elsewhere. Before randomisation, all participants received maximally tolerated doses of angiotensin-converting enzyme inhibitors or AT1-receptor blockers for at least",
      "page": 3,
      "mention_count": 1,
      "pages_mentioned": [
        3
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Monoclonal Gammopathy of Undetermined Significance",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "severe form",
      "preferred_label": "Mucopolysaccharidosis type 2, severe form",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": true,
      "category": "rare_disease",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": null,
        "orpha": "ORPHA:217085",
        "umls": null,
        "mesh": null
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:217085",
          "display": null
        }
      ],
      "context": "C3 glomerulopathy is an ultra-rare and severe form of primary chronic glomerulonephritis with an estimated",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphanet_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "membranoproliferative glomerulonephritis",
      "preferred_label": "membranoproliferative glomerulonephritis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "nephrology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0018904",
        "orpha": "Orphanet:54370",
        "umls": null,
        "mesh": "D015432"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0018904",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:11982",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:583.2",
          "display": null
        },
        {
          "system": "MedDRA",
          "code": "MedDRA:10018370",
          "display": null
        },
        {
          "system": "NANDO",
          "code": "NANDO:2200123",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:54370",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:80321008",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D015432",
          "display": "Glomerulonephritis Membranoproliferative"
        }
      ],
      "context": "26 Downward L, Wong K, Proudfoot C, Webb NJA, Wong E, Gale D. Patient characteristics and renal outcomes of C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in the UK: a retrospective analysis of 287 patients in the UK National Registry of Rare Kidney Diseases (RaDaR). J Am Soc Nephrol 2023; 34 (11S): S271-72.",
      "page": 11,
      "mention_count": 2,
      "pages_mentioned": [
        11
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Complement Factor H Deficiency",
        "Glomerulonephritis sparse hair telangiectases",
        "Membranoproliferative Glomerulonephritis X-Linked"
      ],
      "pubtator_normalized_name": "Glomerulonephritis Membranoproliferative",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "EMA",
      "preferred_label": "Epilepsy with eyelid myoclonia",
      "abbreviation": "EMA",
      "confidence": 0.95,
      "is_rare_disease": true,
      "category": "neurology",
      "codes": {
        "icd10": "G40.3",
        "icd11": "8A61.2Y",
        "snomed": null,
        "mondo": null,
        "orpha": "ORPHA:139431",
        "umls": null,
        "mesh": "D004614"
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:139431",
          "display": null
        },
        {
          "system": "ICD-10",
          "code": "G40.3",
          "display": null
        },
        {
          "system": "ICD-11",
          "code": "8A61.2Y",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D004614",
          "display": "Emaciation"
        }
      ],
      "context": "Before the approval of iptacopan (FABHALTA) for C3 glomerulopathy by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in 2025,’ there were no treatment options for C3 glomerulopathy that target the underlying disease pathogenesis. Current guideline recommendations for C3 glomerulopathy rely on supportive treatments—eg, blockade of the renin— angiotensin—aldosterone system (RAAS) — with angiotensin-converting enzy",
      "page": 2,
      "mention_count": 1,
      "pages_mentioned": [
        2
      ],
      "lexicon_source": "2025_08_rare_disease_acronyms.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Emanuel syndrome"
      ],
      "pubtator_normalized_name": "Emaciation",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "crescentic glomerulonephritis",
      "preferred_label": "crescentic glomerulonephritis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "nephrology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0017236",
        "orpha": "Orphanet:280569",
        "umls": "UMLS:C0221239",
        "mesh": null
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0017236",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:4776",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:583.4",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:113155",
          "display": null
        },
        {
          "system": "MedDRA",
          "code": "MedDRA:10018378",
          "display": null
        },
        {
          "system": "NANDO",
          "code": "NANDO:1200723",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C35264",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:280569",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:236392004",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0221239",
          "display": null
        }
      ],
      "context": "73 m? or higher at screening and day —15 before randomisation. Vaccination against Neisseria meningitidis and Streptococcus pneumoniae before study entry or during the screening period was mandatory. Exclusion criteria included receipt of any cell or solid organ transplantation, rapidly progressive crescentic glomerulonephritis, kidney biopsy showing interstitial fibrosis or tubular atrophy, and monoclonal gammopathy of undetermined significance. The full list of eligibility criteria is available in the appendix (p 6) and further details on the study population are available elsewhere. Before randomisation, all participan",
      "page": 3,
      "mention_count": 1,
      "pages_mentioned": [
        3
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "IgA nephropathy",
      "preferred_label": "Immunoglobulin A nephropathy",
      "abbreviation": "IgAN",
      "confidence": 1.0,
      "is_rare_disease": true,
      "category": "nephrology",
      "codes": {
        "icd10": "N02",
        "icd11": "MF8Y",
        "snomed": "236407003",
        "mondo": null,
        "orpha": "ORPHA:34145",
        "umls": "C0017661",
        "mesh": "D005922"
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:34145",
          "display": null
        },
        {
          "system": "ICD-10",
          "code": "N02",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "N02.B",
          "display": null
        },
        {
          "system": "ICD-11",
          "code": "MF8Y",
          "display": null
        },
        {
          "system": "SNOMED-CT",
          "code": "236407003",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "C0017661",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D005922",
          "display": null
        }
      ],
      "context": "loop, thus preventing downstream generation of alternative pathway C5 convertase, C3a and C5a anaphylatoxins, and the membrane attack complex. Iptacopan is also approved for the treatment of adults with paroxysmal nocturnal haemoglobinuria and for the reduction of proteinuria in adults with primary IgA nephropathy. In a phase 2 study, 12-week iptacopan treatment resulted in proteinuria reduction and stabilisation of estimated glomerular filtration rate (eGFR) in patients with C3 glomerulopathy. These effects persisted 9 months later, when assessed as part of the extension study. The improvements in kidney fu",
      "page": 2,
      "mention_count": 1,
      "pages_mentioned": [
        2
      ],
      "lexicon_source": "disease_lexicon_igan.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Glomerulonephritis IGA",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "primary IgA nephropathy",
      "preferred_label": "IgA glomerulonephritis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "nephrology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0005342",
        "orpha": "Orphanet:34145",
        "umls": "UMLS:C0017661",
        "mesh": "MESH:D005922"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0005342",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:2986",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0004194",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:583.9",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:9032",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D005922",
          "display": null
        },
        {
          "system": "NANDO",
          "code": "NANDO:2200121",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C34643",
          "display": null
        },
        {
          "system": "NORD",
          "code": "NORD:1298",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:34145",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:68779003",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0017661",
          "display": null
        }
      ],
      "context": "ication loop, thus preventing downstream generation of alternative pathway C5 convertase, C3a and C5a anaphylatoxins, and the membrane attack complex. Iptacopan is also approved for the treatment of adults with paroxysmal nocturnal haemoglobinuria and for the reduction of proteinuria in adults with primary IgA nephropathy. In a phase 2 study, 12-week iptacopan treatment resulted in proteinuria reduction and stabilisation of estimated glomerular filtration rate (eGFR) in patients with C3 glomerulopathy. These effects persisted 9 months later, when assessed as part of the extension study. The improvements in kidney fu",
      "page": 2,
      "mention_count": 1,
      "pages_mentioned": [
        2
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Glomerulonephritis IGA",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "CKD",
      "preferred_label": "Chronic Kidney Disease",
      "abbreviation": "CKD",
      "confidence": 0.95,
      "is_rare_disease": true,
      "category": "nephrology",
      "codes": {
        "icd10": "N18.9",
        "icd11": "GB61.Z",
        "snomed": null,
        "mondo": null,
        "orpha": null,
        "umls": null,
        "mesh": "D051436"
      },
      "all_identifiers": [
        {
          "system": "ICD-10",
          "code": "N18.9",
          "display": null
        },
        {
          "system": "ICD-11",
          "code": "GB61.Z",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D051436",
          "display": "Renal Insufficiency Chronic"
        }
      ],
      "context": "Historical serum creatinine data over the 2 years efore study randomisation were systematically collected for all 74 participants and were used to calculate eGFR using the CKD-EPI formula (appendix 7), consistent with the calculation of eGFR during the study. These data allowed a robust comparison of the annualised eGFR slope before the initiation of iptacopan treatment and the slope after the start of treatment. In the prespecified analysis (appendix p 11, 199, 221), th",
      "page": 8,
      "mention_count": 1,
      "pages_mentioned": [
        8
      ],
      "lexicon_source": "2025_08_rare_disease_acronyms.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Kidney Failure Chronic",
        "Chronic Kidney Disease-Mineral and Bone Disorder",
        "Chronic Kidney Diseases of Uncertain Etiology"
      ],
      "pubtator_normalized_name": "Renal Insufficiency Chronic",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "pneumococcal infection",
      "preferred_label": "pneumococcal infection",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "pulmonology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0005114",
        "orpha": null,
        "umls": "UMLS:C0032269",
        "mesh": "MESH:D011008"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0005114",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0000772",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:041.2",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:18528",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D011008",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:16814004",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0032269",
          "display": null
        }
      ],
      "context": "For the open-label period; the overall frequency of adverse events in the combined safety set was similar to that reported in the 6-month double-blind treatment period (appendix p 22). One participant, who tested blood culture positive for $ pneumoniae in the double-blind period, had a pneumococcal infection in the open-label period, which were both resolved with a standard course of antibiotics (appendix pp 13, 22). Infection with encapsulated organisms is an important risk associated with all complement inhibitors, including iptacopan.",
      "page": 9,
      "mention_count": 1,
      "pages_mentioned": [
        9
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Pneumococcal Infections",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "Dense deposit disease",
      "preferred_label": "Dense deposit disease",
      "abbreviation": "DDD",
      "confidence": 1.0,
      "is_rare_disease": true,
      "category": "rare_disease",
      "codes": {
        "icd10": "N03.6",
        "icd11": null,
        "snomed": "236392004",
        "mondo": null,
        "orpha": "ORPHA:93571",
        "umls": null,
        "mesh": "D015432"
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:93571",
          "display": null
        },
        {
          "system": "ICD-10",
          "code": "N03.6",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "N03.6",
          "display": null
        },
        {
          "system": "SNOMED-CT",
          "code": "236392004",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D015432",
          "display": null
        }
      ],
      "context": "aselineC3 (mg/L), mean (SD) 316-8 (243-41) 339:3 (227-96) Age at C3 glomerulopathy 22.0 (10-88) 25:3 (10-80) diagnosis (years), mean (SD) — Years since C3 glomerulopathy diagnosis @yEtS 159%) BEN) 22 years 3 (61%) 21 (58%) C3 glomerulopathy subtype at diagnosis 3 lomervlonephritis 26 (68%) 32 (89%) Dense deposit disease 9 (24%) 1(3%) Mixed C3 glomerulonephritis 2 (5%) 2 (6%) and dense deposit disease Unknown 1(3%) 1(3%) Corticosteroid treatment, 16 (42%) 17 (47%) mycophenolic acid treatment, or both, at time of random allocation",
      "page": 4,
      "mention_count": 1,
      "pages_mentioned": [
        4
      ],
      "lexicon_source": "disease_lexicon_c3g.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Glomerulonephritis Membranoproliferative",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "C3 glomerulonephritis",
      "preferred_label": "C3 glomerulonephritis",
      "abbreviation": "C3GN",
      "confidence": 1.0,
      "is_rare_disease": true,
      "category": "nephrology",
      "codes": {
        "icd10": "N03.6",
        "icd11": null,
        "snomed": "722157000",
        "mondo": null,
        "orpha": "ORPHA:329903",
        "umls": null,
        "mesh": "C567033"
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:329903",
          "display": null
        },
        {
          "system": "ICD-10",
          "code": "N03.6",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "N03.6",
          "display": null
        },
        {
          "system": "SNOMED-CT",
          "code": "722157000",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "C567033",
          "display": "Glomerulonephritis With Isolated C3 Deposits And Factor I Deficiency"
        }
      ],
      "context": "339:3 (227-96) Age at C3 glomerulopathy 22.0 (10-88) 25:3 (10-80) diagnosis (years), mean (SD) — Years since C3 glomerulopathy diagnosis @yEtS 159%) BEN) 22 years 3 (61%) 21 (58%) C3 glomerulopathy subtype at diagnosis 3 lomervlonephritis 26 (68%) 32 (89%) Dense deposit disease 9 (24%) 1(3%) Mixed C3 glomerulonephritis 2 (5%) 2 (6%) and dense deposit disease Unknown 1(3%) 1(3%) Corticosteroid treatment, 16 (42%) 17 (47%) mycophenolic acid treatment, or both, at time of random allocation",
      "page": 4,
      "mention_count": 1,
      "pages_mentioned": [
        4
      ],
      "lexicon_source": "disease_lexicon_c3g.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Complement Factor H Deficiency"
      ],
      "pubtator_normalized_name": "Glomerulonephritis With Isolated C3 Deposits And Factor I Deficiency",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "hypertension",
      "preferred_label": "hypertensive disorder",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": "ICD10CM:I15",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0005044",
        "orpha": null,
        "umls": "UMLS:C0020538",
        "mesh": "MESH:D006973"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0005044",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:10763",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0000537",
          "display": null
        },
        {
          "system": "HP",
          "code": "HP:0000822",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:I15",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:997.91",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:6969",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D006973",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C3117",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:38341003",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0020538",
          "display": null
        }
      ],
      "context": "Iptacopan 200 mg_ Placebo (n=38) (n=36) (Continued from previous column) Baseline eGFR <90 mL/min per 1.73 m= 19 (50%) 12 (33%) 290 mL/min per 1.73 m 19 (50%) 24 (67%) Has hypertension 23 (61%) 18 (50%) Sitting systolic blood 125-8 (1330) 122.6 (11-43) pressure (mm Hg), mean (SD) Sitting diastolic blood 777 (8:77) 777 (8-47) Pressure (mmHg), mean (SD) BaselineC3 (mg/L), mean (SD) 316-8 (243-41) 339:3 (227-96) Age at C3 glomerulopathy 22.0 (10-88) 25:3 (10-80) diagnosis (years), m",
      "page": 4,
      "mention_count": 1,
      "pages_mentioned": [
        4
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "kidney inflammation",
      "preferred_label": "kidney inflammation",
      "abbreviation": null,
      "confidence": 0.85,
      "is_rare_disease": false,
      "category": "nephrology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0001166",
        "orpha": null,
        "umls": "UMLS:C0027697",
        "mesh": "MESH:D009393"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0001166",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:10952",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:1002050",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:583.9",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:14328",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D009393",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C26833",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:52845002",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0027697",
          "display": null
        }
      ],
      "context": "C3 glomerulopathy is caused by overactivation of the alternative complement pathway in both plasma and the glomerular microenvironment.** Such overactivation leads to the accumulation of complement proteins, mainly C3 activation products, in the glomeruli, which triggers kidney inflammation, resulting in glomerular injury.”* Complement factor B is an essential component of C3 convertase, which drives overactivation of the alternative pathway, and therefore represents a prime target for alternative pathway inhibition.**",
      "page": 2,
      "mention_count": 1,
      "pages_mentioned": [
        2
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "Acute kidney injury",
      "preferred_label": "acute kidney injury",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "nephrology",
      "codes": {
        "icd10": "ICD10CM:N17",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0002492",
        "orpha": null,
        "umls": "UMLS:C2609414",
        "mesh": "MESH:D058186"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0002492",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:3021",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:N17",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:388570",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D058186",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C26808",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C2609414",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:476391827",
          "display": null
        }
      ],
      "context": "ne treatment-emergent adverse event Mild 19 (50%) 21 (58%) Moderate 9 (24%) 2 (6%) Severe 2(5%) 1 (3%) Suspected to be related to study 7 (18%) 4 (11%) medication Serious adverse events 3 (8%) 1(3%) Blood culture positive for 1(3%) Streptococcus pneumoniae Infected bite 1(3%) Chest discomfort 1(3%) Acute kidney injury 0 1(3%) Ascites fe) 1(3%) Adverse events leading to study to) ie) drug discontinuation Deaths te}",
      "page": 9,
      "mention_count": 1,
      "pages_mentioned": [
        9
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Acute Kidney Injury",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "glomerulonephritis",
      "preferred_label": "glomerulonephritis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "nephrology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0002462",
        "orpha": null,
        "umls": "UMLS:C0017658",
        "mesh": "MESH:D005921"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0002462",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:2921",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:6516",
          "display": null
        },
        {
          "system": "HP",
          "code": "HP:0000099",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:583.9",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:6616",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D005921",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C26784",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:36171008",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0017658",
          "display": null
        }
      ],
      "context": "C3 glomerulopathy is an ultra-rare and severe form of primary chronic glomerulonephritis with an estimated",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Glomerulonephritis",
        "Glomerulonephritis IGA",
        "Glomerulonephritis Membranoproliferative"
      ],
      "pubtator_normalized_name": "Glomerulonephritis Membranous",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "BEN",
      "preferred_label": "Balkan nephropathy",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "nephrology",
      "codes": {
        "icd10": "ICD10CM:N15.0",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0007416",
        "orpha": null,
        "umls": "UMLS:C0004698",
        "mesh": "MESH:D001449"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0007416",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:3052",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0007164",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:N15.0",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:583.89",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:495",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D001449",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C123025",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "OMIM:124100",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:26121002",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0004698",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:18497836",
          "display": null
        }
      ],
      "context": "1-43) pressure (mm Hg), mean (SD) Sitting diastolic blood 777 (8:77) 777 (8-47) Pressure (mmHg), mean (SD) BaselineC3 (mg/L), mean (SD) 316-8 (243-41) 339:3 (227-96) Age at C3 glomerulopathy 22.0 (10-88) 25:3 (10-80) diagnosis (years), mean (SD) — Years since C3 glomerulopathy diagnosis @yEtS 159%) BEN) 22 years 3 (61%) 21 (58%) C3 glomerulopathy subtype at diagnosis 3 lomervlonephritis 26 (68%) 32 (89%) Dense deposit disease 9 (24%) 1(3%) Mixed C3 glomerulonephritis 2 (5%) 2 (6%) and dense deposit disease Unknown 1(3%) 1(3%) Corticosteroid treatment, 16 (42%) 17 (47%) mycophenolic acid treatment",
      "page": 4,
      "mention_count": 1,
      "pages_mentioned": [
        4
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Balkan Nephropathy",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "C3G",
      "preferred_label": "C3 glomerulopathy",
      "abbreviation": "C3G",
      "confidence": 1.0,
      "is_rare_disease": true,
      "category": "nephrology",
      "codes": {
        "icd10": "N03.6",
        "icd11": null,
        "snomed": "722156009",
        "mondo": null,
        "orpha": "ORPHA:329918",
        "umls": null,
        "mesh": "D000094263"
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:329918",
          "display": null
        },
        {
          "system": "ICD-10",
          "code": "N03.6",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "N03.6",
          "display": null
        },
        {
          "system": "SNOMED-CT",
          "code": "722156009",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D000094263",
          "display": null
        }
      ],
      "context": "David Kavanagh*, Andrew S Bomback*, Marina Vivarelli, Carla M Nester, Giuseppe Remuzzi, Ming-Hui Zhao, Edwin K S Wong, Yaqin Wang, Induja Krishnan, Imelda Schuhmann, Angelo J Trapani, Nicholas J A Webb, Matthias Meier, Ruben K Israni, Richard J H Smith, on behalf of APPEAR-C3G investigatorst",
      "page": 1,
      "mention_count": 2,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "disease_lexicon_c3g.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Complement Factor H Deficiency"
      ],
      "pubtator_normalized_name": "Complement Factor I Deficiency",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "MD",
      "preferred_label": "Menkes disease",
      "abbreviation": "MD",
      "confidence": 0.6,
      "is_rare_disease": true,
      "category": "rare_disease",
      "codes": {
        "icd10": "E83.0",
        "icd11": "5C64.0Y",
        "snomed": null,
        "mondo": null,
        "orpha": "ORPHA:565",
        "umls": null,
        "mesh": "D007706"
      },
      "all_identifiers": [
        {
          "system": "ORPHA",
          "code": "ORPHA:565",
          "display": null
        },
        {
          "system": "ICD-10",
          "code": "E83.0",
          "display": null
        },
        {
          "system": "ICD-11",
          "code": "5C64.0Y",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D007706",
          "display": "Menkes Kinky Hair Syndrome"
        }
      ],
      "context": "n Tyne, UK (Prof D Kavanagh FRCP, EK S Wong FRCP PhD); National Renal Complement Therapeutics Centre, Royal Victoria Infirmary, Newcastle upon Tyne, UK (Prof D Kavanagh, EK S Wong); David Koch Jr Glomerular Kidney Center, Columbia University Irving Medical Center, New York City, NY, USA (AS Bomback MD MPH); Bambino Gest Children’s Hospital, IRCCS, Rome, Italy (M Vivarelli MD); Stead Family Children’s Hospital, University of lowa, lowa City, IA, USA (Prof C M Nester MD); Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy (Prof G Remuzzi MD); Peking University First Hospital, Be",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_rare_disease_acronyms.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Menkes Kinky Hair Syndrome",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "kidney disease",
      "preferred_label": "kidney disease",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "nephrology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0005240",
        "orpha": null,
        "umls": "UMLS:C0022658",
        "mesh": "MESH:D007674"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0005240",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:557",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0003086",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:583.81",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:9635",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D007674",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C3149",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:90708001",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0022658",
          "display": null
        }
      ],
      "context": "C3 glomerulopathy is an ultra-rare, progressive kidney disease that is caused by overactivation of the complement alternative pathway. There were no targeted treatments before iptacopan (LNP023), which was approved for the treatment of adult patients with C3 glomerulopathy by both the US Food and Drug Administration and the European Medicines Agency in 2025. C",
      "page": 2,
      "mention_count": 1,
      "pages_mentioned": [
        2
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Renal Insufficiency Chronic",
        "Kidney Failure Chronic",
        "Glomerulonephritis"
      ],
      "pubtator_normalized_name": "Kidney Diseases",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "kidney failure",
      "preferred_label": "kidney failure",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "nephrology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0001106",
        "orpha": null,
        "umls": "UMLS:C0035078",
        "mesh": "MESH:D051437"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0001106",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:1074",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:1002048",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:586",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:11177",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D051437",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C4376",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:42399005",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0035078",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:761526554",
          "display": null
        }
      ],
      "context": "ction in proteinuria and eGFR stabilisation. lptacopan showed a rapid onset of action, and the efficacy was sustained to 12 months. Based on real-world evidence, the level of proteinuria reduction and eGFR stabilisation observed with iptacopan in APPEAR-C3G would be expected to decrease the risk of kidney failure in the long term. Based on these efficacy results and acceptable safety profile, iptacopan has the potential to fulfil the unmet need for a targeted treatment for C3 glomerulopathy.",
      "page": 2,
      "mention_count": 1,
      "pages_mentioned": [
        2
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Acute Kidney Injury",
        "Kidney Failure Chronic",
        "Hyperuricemic Nephropathy Familial Juvenile 2"
      ],
      "pubtator_normalized_name": "Renal Insufficiency",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "glomerulopathy",
      "preferred_label": "glomerulopathy",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "nephrology",
      "codes": {
        "icd10": "ICD10CM:N00-N08",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0019722",
        "orpha": "Orphanet:93548",
        "umls": null,
        "mesh": "D015433"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0019722",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:1002049",
          "display": null
        },
        {
          "system": "GTR",
          "code": "GTR:AN0966176",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:N00-N08",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C120887",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:93548",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:197679002",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D015433",
          "display": "Glomerulonephritis Membranous"
        }
      ],
      "context": "d by the geometric mean of two 24-h urine collections at baseline. Baseline eGFR was defined as the arithmetic mean of two eGFR values at the day-15 visit (before randomisation) and the day 1 visit. Hypertension is defined based on hypertension at diagnosis as reported by the investigator on the (3 glomerulopathy medical history case report form and the pre-defined hypertension terms taken from patient medical history. eGFR=estimated glomerular filtration rate. UPCR=urine protein creatinine ratio.",
      "page": 4,
      "mention_count": 1,
      "pages_mentioned": [
        4
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Nephrosis Lipoid",
        "Glomerulonephritis Membranoproliferative",
        "Glomerulopathy with fibronectin deposits"
      ],
      "pubtator_normalized_name": "Glomerulonephritis Membranous",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "rare disease",
      "preferred_label": "rare disease",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "rare_disease",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0021200",
        "orpha": null,
        "umls": null,
        "mesh": "MESH:D035583"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0021200",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D035583",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C4873",
          "display": null
        }
      ],
      "context": "n adult patients with C3 glomerulopathy. Due to the ultrarare prevalence of C3 glomerulopathy, the study was conducted in 35 hospitals or medical centres across 18 countries (appendix p 3). Sites were chosen based on their previous clinical trial experience but, given C3 glomerulopathy is an ultra-rare disease, it was expected that most sites would have few cases therefore selection was not based on an expected number of participants and there were no restrictions related to insurance networks. Further details of the study design have been described elsewhere (appendix p 23). The trial was conducted in a",
      "page": 3,
      "mention_count": 1,
      "pages_mentioned": [
        3
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Rare Diseases",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "proteinuria",
      "preferred_label": "proteinuria",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": "ICD10CM:R80",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0003634",
        "orpha": null,
        "umls": "UMLS:C0033687",
        "mesh": "MESH:D011507"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0003634",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:576",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:R80",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:791.0",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:10976",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D011507",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0033687",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:930895737",
          "display": null
        }
      ],
      "context": "or both (yes or no). During the 6-month double-blind period, participants orally received either iptacopan 200 mg twice daily or placebo; this was followed by a 6-month open-label period in which all participants received iptacopan 200 mg twice daily. The primary endpoint was relative reduction in proteinuria (measured by logtransformed ratio to baseline in UPCR sampled from a 24-h urine collection) at 6 months. The primary analyses were done in the full analysis set (ie, all participants to whom study treatment was assigned by randomisation); all participants who received at least one dose of study tre",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Pre-Eclampsia",
        "Donnai-Barrow syndrome",
        "Low Molecular Weight Proteinuria with Hypercalciuria and Nephrocalcinosis"
      ],
      "pubtator_normalized_name": "Proteinuria",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "meningitis",
      "preferred_label": "meningitis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0021108",
        "orpha": null,
        "umls": "UMLS:C0025289",
        "mesh": "MESH:D008581"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0021108",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:322.9",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:6298",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D008581",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C26828",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:7180009",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0025289",
          "display": null
        }
      ],
      "context": "ts were mild to moderate in severity. Infections caused by encapsulated bacteria are an increased risk during complement inhibition.” The two serious treatment-related pneumococcal infections in a single participant in the study resolved with a standard course of antibiotics. There were no cases of meningitis or meningococcal sepsis. The safety profile of iptacopan in the APPEAR-C3G trial is consistent with that observed across other studies in C3 glomerulopathy and studies in other diseases (IgA nephropathy and paroxysmal! nocturnal haemoglobinuria).\"\"”**",
      "page": 10,
      "mention_count": 1,
      "pages_mentioned": [
        10
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Meningism",
        "Meningitis Aseptic",
        "Meningitis Pneumococcal"
      ],
      "pubtator_normalized_name": "Meningitis Bacterial",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "condition",
      "preferred_label": "condition",
      "abbreviation": null,
      "confidence": 0.65,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0000001",
        "orpha": "Orphanet:377788",
        "umls": "UMLS:C0012634",
        "mesh": "MESH:D004194"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0000001",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:4",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:799.9",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:4347",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D004194",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C2991",
          "display": null
        },
        {
          "system": "OGMS",
          "code": "OGMS:0000031",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:377788",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:64572001",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0012634",
          "display": null
        }
      ],
      "context": "tive treatments is limited to small, retrospective observational studies and such treatments often come with considerable side-effects. Therefore, a concerted effort is required to develop a novel, targeted therapy for C3 glomerulopathy, to address the high unmet medical need for patients with this condition.",
      "page": 2,
      "mention_count": 2,
      "pages_mentioned": [
        2,
        9
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Chronic Disease",
        "Precancerous Conditions",
        "Muscular Diseases"
      ],
      "pubtator_normalized_name": "Neurodegenerative Diseases",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "hepatitis",
      "preferred_label": "Hepatitis",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "gastroenterology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0002251",
        "orpha": null,
        "umls": "UMLS:C0019158",
        "mesh": "MESH:D006505"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0002251",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:2237",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:571.41",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:5515",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D006505",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C3095",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:197268000",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0019158",
          "display": null
        }
      ],
      "context": "Data are presented for the full analysis set (ie, all participants to whom study treatment was assigned by randomisation). *Some participants did not complete screening or run-in period for more than one reason, the full list includes: did not meet blood pressure criteria; had active hepatitis or abnormal liver function tests; unable to communicate with investigator or comply with study requirements; did not have diagnosis confirmed on renal biopsy within 12 months; was not on stable dose of antiproteinuric medications for 90 or more days; and participant decision +Two participants rando",
      "page": 3,
      "mention_count": 1,
      "pages_mentioned": [
        3
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Hepatitis C Chronic",
        "Hepatitis C",
        "Hepatitis E"
      ],
      "pubtator_normalized_name": "Hepatitis B",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "infection",
      "preferred_label": "infection",
      "abbreviation": null,
      "confidence": 0.85,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": "ICD10CM:A00-B99",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0005550",
        "orpha": null,
        "umls": "UMLS:C0009450",
        "mesh": "MESH:D003141"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0005550",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:0050117",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0005741",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:A00-B99",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:136.9",
          "display": null
        },
        {
          "system": "IDO",
          "code": "IDO:0000436",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:1057",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D003141",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C26726",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:40733004",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0009450",
          "display": null
        }
      ],
      "context": "group) or moderate (nine [24%] in the iptacopan group; two (6%) in the placebo group) severity. Overall, three (8%) participants in the iptacopan group and one (3%) participant in the placebo group had serious adverse events in the double-blind period. There were two reported infection-related serious adverse events, both in the iptacopan group (table 2).",
      "page": 9,
      "mention_count": 1,
      "pages_mentioned": [
        9
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "COVID-19",
        "HIV Infections",
        "Virus Diseases"
      ],
      "pubtator_normalized_name": "Infections",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "injury",
      "preferred_label": "injury",
      "abbreviation": null,
      "confidence": 0.85,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0021178",
        "orpha": null,
        "umls": null,
        "mesh": "MESH:D014947"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0021178",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0000546",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D014947",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C3671",
          "display": null
        }
      ],
      "context": "is caused by overactivation of the alternative complement pathway in both plasma and the glomerular microenvironment.** Such overactivation leads to the accumulation of complement proteins, mainly C3 activation products, in the glomeruli, which triggers kidney inflammation, resulting in glomerular injury.”* Complement factor B is an essential component of C3 convertase, which drives overactivation of the alternative pathway, and therefore represents a prime target for alternative pathway inhibition.**",
      "page": 2,
      "mention_count": 1,
      "pages_mentioned": [
        2
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Chemical and Drug Induced Liver Injury",
        "Smoke Inhalation Injury",
        "Acute Kidney Injury"
      ],
      "pubtator_normalized_name": "Wounds and Injuries",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "March",
      "preferred_label": "MARCH",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0009359",
        "orpha": "Orphanet:500135",
        "umls": "UMLS:C1856053",
        "mesh": "MESH:C565507"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0009359",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:0080327",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:17922",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:343465",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:C565507",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "OMIM:236500",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:500135",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C1856053",
          "display": null
        }
      ],
      "context": "addition to supportive care in patients with native C3 glomerulopathy. Along with the published phase 2 results,\"°” the phase 3 results described in this Article provided the evidence for approval of iptacopan by the US FDA (in March 2025) and the EMA (in April 2025).",
      "page": 3,
      "mention_count": 1,
      "pages_mentioned": [
        3
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Fractures Stress",
        "Hemoglobinuria Paroxysmal",
        "Marchiafava-Bignami Disease"
      ],
      "pubtator_normalized_name": "Gait Disorders Neurologic",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "SAS",
      "preferred_label": "SAS",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0100147",
        "orpha": "Orphanet:576278",
        "umls": null,
        "mesh": null
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0100147",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:22326",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:576278",
          "display": null
        }
      ],
      "context": "analysis. All analyses were carried out as per the study protocol or as prespecified in the statistical analysis plan (appendix pp 152-259). Details on the statistical hypotheses, models, and analysis methods are available in the appendix (pp 8-11, 23). All statistical analyses were performed with SAS (version 9.4). An independent data monitoring committee was established and routinely reviewed unblinded safety data at 4-month intervals.",
      "page": 6,
      "mention_count": 1,
      "pages_mentioned": [
        6
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "CMN",
      "preferred_label": "CMn",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0017043",
        "orpha": "Orphanet:2665",
        "umls": "UMLS:C1332965",
        "mesh": null
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0017043",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:4773",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:1493",
          "display": null
        },
        {
          "system": "ICDO",
          "code": "ICDO:8960/1",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:232058",
          "display": null
        },
        {
          "system": "MedDRA",
          "code": "MedDRA:10070665",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C6569",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:2665",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C1332965",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:2001572901",
          "display": null
        }
      ],
      "context": "All authors had access to the study data. DK, CMN, RKI, YW, IK, and IS have accessed and verified the patient-level study data. DK, ASB, MV, CMN, GR, M-HZ, EKSW, YW, IK, AJT, NJAW, MM, and RJHS were involved in the conceptualisation of the published work. YW, IK, and IS participated in data curation. YW and IK conducted the formal analysis. DK, AS",
      "page": 10,
      "mention_count": 1,
      "pages_mentioned": [
        10
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    }
  ]
}